BRCA1 and ovarian carcinoma: Among patients with platinum-resistant ovarian cancers and mutation reversion, two out of three were resistant to subsequent PARPi, whereas, surprisingly, one patient still derived benefit from PARPi and experienced a partial response despite BRCA1 reversion mutation to wild type and a platinum-resistant disease.